Thought leadership we rely on
At the heart of our innovation is a team dedicated to research and new discovery. Our Scientific Advisory Board consists of industry-leading experts with a unified mission to help us create meaningful medicines that improve patients’ lives.
Daniel D. Von Hoff, M.D., F.A.C.P.
Chairman of the Advisory Board
Daniel D. Von Hoff, M.D., F.A.C.P., is currently Physician‑in‑Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Honor Health’s Clinical Research Institute. In addition, Dr. Von Hoff is a Clinical Professor of Medicine at the University of Arizona.
Johanna C. Bendell, M.D.
Johanna C. Bendell, M.D., serves as Chief Development Officer for Sarah Cannon Research Institute.
Kenneth C. Anderson, M.D.
Kenneth C. Anderson M.D., is a Program Director for the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics. He is also the Kraft Family Professor of Medicine at Harvard Medical School.
Nicholas J. Vogelzang, M.D.
Nicholas J. Vogelzang, M.D., is a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as Medical Director of the Research Executive Committee and Associate Chair of the Development Therapeutics and Genitourinary Committees for US Oncology Research.
Stephan A. Grupp, M.D., Ph.D.
Stephan A. Grupp, M.D., Ph.D., is Director of the Cancer Immunotherapy Program, Director of Translational Research for the Center for Childhood Cancer Research at Children’s Hospital of Philadelphia, and Medical Director of the Stem Cell Laboratory.
Manuel Hidalgo Medina, M.D., Ph.D.
Manuel Hidalgo Medina, M.D., Ph.D., is the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York-Presbyterian Hospital.